Shots: The Progeria Research Foundation and Eiger reported the US FDA’s approval of Zokinvy (lonafarnib) for the treatment of HGPS or progeria and processing-deficient progeroid laminopathies Zokinvy reduced the incidence of mortality by 60% & increased the average survival time by 2.5 yrs. Additionally, the FDA has issued an RPD priority review voucher to Eiger […]Read More
Shots: The US FDA has accepted the NDA for accelerated review of Zokinvy (lonafarnib) and has granted PR designation with the anticipated PDUFA date as Nov 20, 2020. The US FDA is not planning to hold an advisory committee meeting to discuss the application The NDA includes the data from the study published in JAMA […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
